Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd

Published:

Format:  Hardcopy and Adobe PDF

Price:  US$1,500

Contact: Mr.Humphrey  

Tel.: 86-10-58110925            Fax:  86-10-58110918

E-mail: [email protected] 

 

    In China 23.8 million people having diabetes, China comes into the procession of middle incidence of diabetes from low incidence. Now China have the most diabetic patients in the world. Insulin is a drug included in catalogue of drugs for basic national medical insurance。Now foreign and joint venture enterprises occupy the major segment of the Chinese insulin market.

   The report presents epidemic trend of diabetes in China, Market shares of different enterprises (brands), sales analysis of key cities etc, based on the accurate data. The report also provides market forecasts and competitive and opportunity analysis in China.

 

 

Summary

1 Overview of epidemic trend of diabetes in China

2 Overview of antidiabetic market in China

3 Development of insulin

  3.1 Pharmaceutical action and classification

  3.2 Current status of clinical usage

  3.3 Development process of insulin in China

4 Market analysis in Chinese insulin market

  4.1 General situation of Chines insulin market

  4.2 Sales situation of different breeds of insulin and insulin analogs

  4.3 Sales analysis of insulin products in different cities

  4.4 Market shares of different enterprises (brands)

    4.1.1 Novo Nordisk Biotechnology Co Ltd

    4.1.2 Suzhou lilly Pharmaceutical Co., Ltd

    4.1.3 Jiangsu Wanbang biochemical medicine Co.,LTD

    4.1.4 Shanghai No.1 Biochemical Pharmaceutical Co. Ltd 

    4.1.5 Tonghua Dongbao Pharmaceutical Company, Ltd

5 Sales analysis of different breeds

  5.1 mono component insulin (McI)

  5.2 insulin

  5.3 protamine zinc insulin

  5.4 Insulin lispro

  5.5 Insulin Aspart

6 Sales forcast and suggestions for marketing